SCHEMBL4516264

SCHEMBL4516264

O=C(O)c1cc(=O)c2cc(O)ccc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NGFR P08138 1/20 0.69
KDM4E B2RXH2 4/20 0.65
GPR35 Q9HC97 3/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
HPGD P15428 2/20 0.65
MAPK1 P28482 2/20 0.65
ALDH1A1 P00352 2/20 0.65
HSD17B10 Q99714 2/20 0.65
GAA P10253 2/20 0.65
GRIN2D O15399 1/20 0.65
GRIN3B O60391 1/20 0.65
CYP1A2 P05177 1/20 0.65
GLA P06280 1/20 0.65
CYP2C19 P33261 1/20 0.65
AHR P35869 1/20 0.65
CHRNA7 P36544 1/20 0.65
GRIN1 Q05586 1/20 0.65
GRIN2A Q12879 1/20 0.65
GRIN2B Q13224 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11615435 0.85 NGFR (0.67) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL11698420 0.84 NGFR (0.71) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL1504031 0.81 MEN1 (0.77) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL8210976 0.81 NGFR (0.67) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL9452339 0.81 NGFR (0.67) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL9452255 0.81 NGFR (0.67) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL9452271 0.81 NGFR (0.67) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL11620057 0.81 KDM4E (0.72) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL11616760 0.80 NGFR (0.74) NGFRKDM4EGPR35MEN1KMT2A
SCHEMBL11643685 0.80 GPR35 (0.65) NGFRKDM4EGPR35MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285544-A Method for separating and preparing natural 6-hydroxykynurenic acid from ginkgo leaves 浙江理工大学绍兴生物医药研究院有限公司 2025-01-10 CN disclosed
WO-2023246355-A1 GINKGO LEAF ORGANIC ACID EXTRACT, METHOD FOR PREARING SAME AND USE THEREOF 浙江康恩贝制药股份有限公司 2023-12-28 WO disclosed
CN-115006435-B Ginkgo leaf organic acid extract and preparation method and application thereof 浙江康恩贝制药股份有限公司 2023-11-28 CN disclosed
CN-114366761-B Preparation method of ginkgo leaf extract rich in organic acid 江苏得乐康生物科技有限公司 2022-11-01 CN disclosed
CN-115006435-A Ginkgo leaf organic acid extract and preparation method and application thereof 浙江康恩贝制药股份有限公司 2022-09-06 CN disclosed
CN-114366761-A Preparation method of ginkgo leaf extract rich in organic acid 江苏得乐康生物科技有限公司 2022-04-19 CN disclosed
CN-103784448-B A kind of preparation method of natural 6-HKA extract and application thereof ZHEJIANG CONBA PHARMACEUTICAL CO., LTD. (CN) 2015-11-18 CN disclosed
US-20090012118-A1 Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2009-01-08 US disclosed
CN-1989127-A Kynurenic acid amide derivatives as NR2B receptor antagonists RICHTER GEDEON VEGYESZET (HU) 2007-06-27 CN disclosed
EP-1771436-A1 KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS Richter Gedeon Vegy Szeti Gy R Rt. (HU) 2007-04-11 EP disclosed
WO-2006010967-A1 KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012118-A1 Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni GRIN1, GRIN2A, GRIN2B NGFR 331/4885KDM4E 2737/4885GPR35 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.